13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001493215
Total reported value
$11.7B
$11.7B
68 檔
16.5%
In Q2 2024, Rtw Investments, LP's U.S. equity holdings reached a combined market value of $11.7B, distributed across 68 disclosed stock positions.
In Q2 2024, Rtw Investments, LP displayed an active expansion posture, initiating 4 new positions and adding to 19 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 8.31% | -1.24% | +382.53% | |
| 2 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 5.90% | -0.11% | — | |
| 3 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 5.78% | — | +3.15% | |
| 4 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 5.57% | — | +10.50% | |
| 5 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.36% | +0.46% | -1.91% | |
| 6 | NTRA | Natera Inc | Stock-Healthcare | 4.35% | -0.17% | — | |
| 7 | ✓ | Merus N V | Stock-Other | 3.82% | — | +1.46% | |
| 8 | INSM | Insmed Inc | Stock-Healthcare | 3.78% | -3.47% | +95.17% | |
| 9 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.50% | +0.14% | -0.42% | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.49% | — | +106.60% | |
| 11 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.45% | -0.04% | -0.88% | |
| 12 | BRKR | Bruker CORP | Stock-Healthcare | 3.40% | — | +2.99% | |
| 13 | MASI* | Masimo CORP | Stock-Other | 2.85% | — | — | |
| 14 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.84% | -0.01% | -0.55% | |
| 15 | ALKS | Alkermes plc | Stock-Healthcare | 2.63% | +0.16% | +16.56% | |
| 16 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.56% | -0.14% | -19.10% | |
| 17 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.28% | +0.30% | +7.77% | |
| 18 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.07% | +1.46% | -54.00% | |
| 19 | PEN | Penumbra Inc | Stock-Healthcare | 2.07% | — | +9.80% | |
| 20 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.97% | — | — | |
| 21 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.88% | +0.45% | — | |
| 22 | ✓ | Immatics NV | Stock-Other | 1.80% | -0.14% | — | |
| 23 | RDNT | Radnet Inc | Stock-Healthcare | 1.69% | +0.17% | +9.14% | |
| 24 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.65% | -2.33% | EXIT | |
| 25 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.44% | -0.54% | +4.28% | |
| 26 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.39% | -1.01% | EXIT | |
| 27 | ARVN | Arvinas Inc | Stock-Other | 1.22% | — | -10.01% | |
| 28 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.19% | +1.13% | +45.93% | |
| 29 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.04% | — | +9.17% | |
| 30 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.92% | +0.62% | +9.21% | |
| 31 | SG7 | Sage Therapeutics Inc | Stock-Other | 0.92% | — | — | |
| 32 | ETNBGBP | 89bio Inc | Stock-Other | 0.92% | — | — | |
| 33 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.88% | -0.25% | — | |
| 34 | OBIO | Orchestra Biomed Holdings In | Stock-Other | 0.71% | — | — | |
| 35 | GKOS | Glaukos CORP | Stock-Healthcare | 0.71% | — | +557.06% | |
| 36 | CGON | Cg Oncology Inc | Stock-Other | 0.66% | +0.46% | +224.91% | |
| 37 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.65% | +0.18% | +1.11% | |
| 38 | NGNE | Neurogene Inc | Stock-Other | 0.60% | +0.10% | +39.19% | |
| 39 | GHRS | GH Research PLC | Stock-Other | 0.60% | +0.53% | — | |
| 40 | VCEL | Vericel CORP | Stock-Other | 0.57% | — | -50.11% | |
| 41 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.56% | — | — | |
| 42 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.28% | +0.13% | — | |
| 43 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 44 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.24% | — | — | |
| 45 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.23% | — | — | |
| 46 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 0.22% | — | — | |
| 47 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.22% | — | — | |
| 48 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.19% | — | — | |
| 49 | REPL | Replimune Group Inc | Stock-Other | 0.16% | +0.14% | — | |
| 50 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.15% | — | -67.66% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MDGL | Madrigal Pharmaceuticals Inc | +6.7% | +382.53% | Add |
| 2 | INSM | Insmed Inc | +3% | +95.17% | Add |
| 3 | RNAGBP | Avidity Biosciences Inc | +2.6% | +10.50% | Add |
| 4 | DYN | Dyne Therapeutics Inc | +2.2% | +106.60% | Add |
| 5 | ✓ | Merus N V | +1.1% | +1.46% | Add |
| 6 | NTRA | Natera Inc | +0.9% | — | Unchanged |
| 7 | ISRG | Intuitive Surgical Inc | +0.8% | +104.50% | Add |
| 8 | GKOS | Glaukos CORP | +0.6% | +557.06% | Add |
| 9 | PTGX | Protagonist Therapeutics Inc | +0.6% | -0.55% | Trim |
| 10 | AXSM | Axsome Therapeutics Inc | +0.5% | +3.15% | Add |
| 11 | ARGX | Argenx Se - Adr | +0.5% | -1.91% | Trim |
| 12 | RDNT | Radnet Inc | +0.5% | +9.14% | Add |
| 13 | CGON | Cg Oncology Inc | +0.4% | +224.91% | Add |
| 14 | PTCT | Ptc Therapeutics Inc | +0.3% | -0.42% | Trim |
| 15 | CGEM | Cullinan Therapeutics Inc | +0.3% | NEW | New buy |
| 16 | OBIO | Orchestra Biomed Holdings In | +0.3% | — | Unchanged |
| 17 | ✓ | Immatics NV | +0.3% | — | Unchanged |
| 18 | TEM | Tempus Ai Inc-cl A | +0.2% | NEW | New buy |
| 19 | URGN | UroGen Pharma Ltd. | +0.2% | +9.21% | Add |
| 20 | REPL | Replimune Group Inc | +0.2% | NEW | New buy |
| 21 | ✓ | +0.1% | NEW | New buy | |
| 22 | AKRO | Akero Therapeutics Inc | -0.1% | — | Unchanged |
| 23 | SYRE | Spyre Therapeutics Inc | -0.1% | +45.93% | Add |
| 24 | TRML | Tourmaline Bio Inc | -0.1% | — | Unchanged |
| 25 | TORCEUR | Adicet Bio Inc | -0.1% | -74.52% | Trim |
| 26 | ✓ | Establishment Labs Holdings In | -0.1% | — | Unchanged |
| 27 | TSHA | Taysha Gene Therapies Inc | -0.1% | +1.11% | Add |
| 28 | PEN | Penumbra Inc | -0.2% | +9.80% | Add |
| 29 | CRGX | Cargo Therapeutics Inc | -0.2% | +9.17% | Add |
| 30 | FULC | Fulcrum Therapeutics Inc | -0.3% | — | Unchanged |
| 31 | ACAD | Acadia Pharmaceuticals Inc | -0.3% | -0.88% | Trim |
| 32 | MASI* | Masimo CORP | -0.3% | — | Unchanged |
| 33 | TARS | Tarsus Pharmaceuticals Inc | -0.3% | +4.28% | Add |
| 34 | CYTK | Cytokinetics Inc | -0.3% | +7.77% | Add |
| 35 | ETNBGBP | 89bio Inc | -0.4% | — | Unchanged |
| 36 | KYTX | Kyverna Therapeutics Inc | -0.5% | — | Unchanged |
| 37 | JANX | Janux Therapeutics Inc | -0.6% | EXIT | Sold out |
| 38 | SG7 | Sage Therapeutics Inc | -0.6% | — | Unchanged |
| 39 | VCEL | Vericel CORP | -0.7% | -50.11% | Trim |
| 40 | TXG | 10x Genomics Inc-class A | -0.7% | -67.66% | Trim |
| 41 | APGE | Apogee Therapeutics Inc | -0.8% | +9.91% | Add |
| 42 | ARVN | Arvinas Inc | -0.8% | -10.01% | Trim |
| 43 | TMO | Thermo Fisher Scientific Inc | -1% | EXIT | Sold out |
| 44 | RCKT | Rocket Pharmaceuticals Inc | -1.1% | — | Unchanged |
| 45 | BRKR | Bruker CORP | -1.2% | +2.99% | Add |
| 46 | SWAVUSD | Shockwave Medical Inc | -1.4% | EXIT | Sold out |
| 47 | SYK | Stryker CORP | -1.7% | EXIT | Sold out |
| 48 | ✓ | Avadel Pharmaceuticals PLC ADR | -2.2% | EXIT | Sold out |
| 49 | RARE | Ultragenyx Pharmaceutical In | -2.8% | -54.00% | Trim |
| 50 | IMCR | Immunocore Holdings Plc-adr | -3.2% | -19.10% | Trim |
According to official SEC Form 13F filings, Rtw Investments, LP reported a total U.S. public equity portfolio value of $11.7B across 68 disclosed positions in Q2 2024.
During Q2 2024, Rtw Investments, LP's top holdings by market value included MDGL (8.3%)、RCKT (5.9%)、AXSM (5.8%). The largest single position, MDGL, represented 8.3% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MDGL, RCKT, AXSM) accounted for 16.5% of total reported equity market value during Q2 2024.
Top New Position Initiated
CGEM
市值: $18.4M
Top Position Liquidated / Trimmed
Avadel Pharmaceuticals PLC ADR
前期市值: $148.6M
In Q2 2024, Rtw Investments, LP made 38 total portfolio adjustments, initiating 4 new buys, adding to 19 positions, trimming 10 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.